AIM thanks the following corporate partners for their continued support in providing resources and education on immunotherapy to the healthcare professional community, helping advance care for patients with cancer.
Felip E, Rojas C, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncology. 2025;36: 775-785.
Albiges L, Bourlon MT, Chac贸n M, Cutuli HJ, Chuken YAL, 呕urawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Erratum in: Ann Oncol. 2026 May 6:S0923-7534(26)00129-8.
NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2026. April 17, 2026.
Long GV, Hauschild A, Santinami M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024;391(18):1709-1720.
Araujo DV, Souza BL, Seibel MF, Fares AF, Liutti VT. Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis. Oncologist. 2025;30(9).
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784.
Felip E, Rojas C, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncology. 2025;36: 775-785.
Albiges L, Bourlon MT, Chac贸n M, Cutuli HJ, Chuken YAL, 呕urawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. Erratum in: Ann Oncol. 2026 May 6:S0923-7534(26)00129-8.
NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2026. April 17, 2026.
Long GV, Hauschild A, Santinami M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024;391(18):1709-1720.
Araujo DV, Souza BL, Seibel MF, Fares AF, Liutti VT. Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis. Oncologist. 2025;30(9).
Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784.